TISIDB

Summary
Symbol	DDX20
Name	DEAD (Asp-Glu-Ala-Asp) box polypeptide 20
Aliases	DP103; GEMIN3; DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 20, 103kD; DEAD box protein 20; DEAD box protein ......
Chromosomal Location	1p21.1-p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm. Nucleus, gem. Note=Localized in subnuclear structures next to coiled bodies, called Gemini of Cajal bodies (Gems).
Domain	PF00270 DEAD/DEAH box helicase PF00271 Helicase conserved C-terminal domain
Function	The SMN complex plays a catalyst role in the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome. Thereby, plays an important role in the splicing of cellular pre-mRNAs. Most spliceosomal snRNPs contain a common set of Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP. In the cytosol, the Sm proteins SNRPD1, SNRPD2, SNRPE, SNRPF and SNRPG are trapped in an inactive 6S pICln-Sm complex by the chaperone CLNS1A that controls the assembly of the core snRNP. Dissociation by the SMN complex of CLNS1A from the trapped Sm proteins and their transfer to an SMN-Sm complex triggers the assembly of core snRNPs and their transport to the nucleus. May also play a role in the metabolism of small nucleolar ribonucleoprotein (snoRNPs).

> Gene Ontology [ TOP ]
Biological Process	GO:0000244 spliceosomal tri-snRNP complex assembly GO:0000375 RNA splicing, via transesterification reactions GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile GO:0000387 spliceosomal snRNP assembly GO:0000398 mRNA splicing, via spliceosome GO:0006397 mRNA processing GO:0006694 steroid biosynthetic process GO:0006913 nucleocytoplasmic transport GO:0007281 germ cell development GO:0007292 female gamete generation GO:0008202 steroid metabolic process GO:0008380 RNA splicing GO:0010501 RNA secondary structure unwinding GO:0019216 regulation of lipid metabolic process GO:0019218 regulation of steroid metabolic process GO:0022412 cellular process involved in reproduction in multicellular organism GO:0022613 ribonucleoprotein complex biogenesis GO:0022618 ribonucleoprotein complex assembly GO:0046890 regulation of lipid biosynthetic process GO:0048477 oogenesis GO:0050810 regulation of steroid biosynthetic process GO:0051169 nuclear transport GO:0051170 nuclear import GO:0071826 ribonucleoprotein complex subunit organization
Molecular Function	GO:0003724 RNA helicase activity GO:0004004 ATP-dependent RNA helicase activity GO:0004386 helicase activity GO:0008026 ATP-dependent helicase activity GO:0008134 transcription factor binding GO:0008186 RNA-dependent ATPase activity GO:0016887 ATPase activity GO:0030674 protein binding, bridging GO:0042623 ATPase activity, coupled GO:0042826 histone deacetylase binding GO:0060090 binding, bridging GO:0070035 purine NTP-dependent helicase activity GO:0070491 repressing transcription factor binding
Cellular Component	GO:0016604 nuclear body GO:0017053 transcriptional repressor complex GO:0032797 SMN complex GO:0034719 SMN-Sm protein complex GO:0090568 nuclear transcriptional repressor complex GO:0090571 RNA polymerase II transcription repressor complex GO:0097504 Gemini of coiled bodies

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa03013 RNA transport
Reactome	R-HSA-74160: Gene Expression R-HSA-194441: Metabolism of non-coding RNA R-HSA-191859: snRNP Assembly

Summary
Symbol	DDX20
Name	DEAD (Asp-Glu-Ala-Asp) box polypeptide 20
Aliases	DP103; GEMIN3; DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 20, 103kD; DEAD box protein 20; DEAD box protein ......
Chromosomal Location	1p21.1-p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between DDX20 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	DDX20
Name	DEAD (Asp-Glu-Ala-Asp) box polypeptide 20
Aliases	DP103; GEMIN3; DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 20, 103kD; DEAD box protein 20; DEAD box protein ......
Chromosomal Location	1p21.1-p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of DDX20 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	logFC: -2.03; FDR: 0.04220	Resistant to T cell-mediated killing
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	DDX20
Name	DEAD (Asp-Glu-Ala-Asp) box polypeptide 20
Aliases	DP103; GEMIN3; DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 20, 103kD; DEAD box protein 20; DEAD box protein ......
Chromosomal Location	1p21.1-p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of DDX20 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.005	0.978
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.242	0.857
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.187	0.853
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.123	0.568
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.113	0.945
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.135	0.949
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.06	0.847
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.128	0.926
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.014	0.993
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.101	0.905
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.537	0.638
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.089	0.169

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of DDX20 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	2.7	4.7	0.294
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	3.4	4	0.587
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	11.1	8.9	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	3.7	-3.7	0.415
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	DDX20
Name	DEAD (Asp-Glu-Ala-Asp) box polypeptide 20
Aliases	DP103; GEMIN3; DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 20, 103kD; DEAD box protein 20; DEAD box protein ......
Chromosomal Location	1p21.1-p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DDX20. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	DDX20
Name	DEAD (Asp-Glu-Ala-Asp) box polypeptide 20
Aliases	DP103; GEMIN3; DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 20, 103kD; DEAD box protein 20; DEAD box protein ......
Chromosomal Location	1p21.1-p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DDX20. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DDX20. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	DDX20
Name	DEAD (Asp-Glu-Ala-Asp) box polypeptide 20
Aliases	DP103; GEMIN3; DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 20, 103kD; DEAD box protein 20; DEAD box protein ......
Chromosomal Location	1p21.1-p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DDX20. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	DDX20
Name	DEAD (Asp-Glu-Ala-Asp) box polypeptide 20
Aliases	DP103; GEMIN3; DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 20, 103kD; DEAD box protein 20; DEAD box protein ......
Chromosomal Location	1p21.1-p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of DDX20 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	DDX20
Name	DEAD (Asp-Glu-Ala-Asp) box polypeptide 20
Aliases	DP103; GEMIN3; DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 20, 103kD; DEAD box protein 20; DEAD box protein ......
Chromosomal Location	1p21.1-p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between DDX20 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	DDX20
Name	DEAD (Asp-Glu-Ala-Asp) box polypeptide 20
Aliases	DP103; GEMIN3; DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 20, 103kD; DEAD box protein 20; DEAD box protein ......
Chromosomal Location	1p21.1-p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting DDX20 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse DDX20